[Combination therapy for the treatment of hypercholesterolemia: primary and secondary prevention].

IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Stefania Angela Di Fusco, Furio Colivicchi
{"title":"[Combination therapy for the treatment of hypercholesterolemia: primary and secondary prevention].","authors":"Stefania Angela Di Fusco, Furio Colivicchi","doi":"10.1714/4425.44226","DOIUrl":null,"url":null,"abstract":"<p><p>The reduction of low-density lipoprotein cholesterol (LDL-C) is the cornerstone of atherosclerotic cardiovascular diseases management, both in primary and secondary prevention. The use of more lipid-lowering agents represents an effective and safe option to reduce LDL-C with the advantage of a better adherence to treatment compared to the use of higher statin dosages as monotherapy. This review focuses on therapeutic targets as recommended in different clinical settings in primary and secondary prevention, and analyzes evidence on the statin/ezetimibe combination use in primary prevention. Furthermore, we discuss the impact of rosuvastain/ezetimibe combination in secondary prevention and report available data on LDL-C reduction and on the effects on atherosclerotic plaques and clinical events.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"26 1","pages":"e17-e22"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4425.44226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

The reduction of low-density lipoprotein cholesterol (LDL-C) is the cornerstone of atherosclerotic cardiovascular diseases management, both in primary and secondary prevention. The use of more lipid-lowering agents represents an effective and safe option to reduce LDL-C with the advantage of a better adherence to treatment compared to the use of higher statin dosages as monotherapy. This review focuses on therapeutic targets as recommended in different clinical settings in primary and secondary prevention, and analyzes evidence on the statin/ezetimibe combination use in primary prevention. Furthermore, we discuss the impact of rosuvastain/ezetimibe combination in secondary prevention and report available data on LDL-C reduction and on the effects on atherosclerotic plaques and clinical events.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Giornale italiano di cardiologia
Giornale italiano di cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信